NewsBite

Csl

Trading DayTrading Day

SYDNEY, AUSTRALIA : Newswire Photos AUGUST 30 2023: A general view of the digital boards at the ASX in Sydney. Picture: NCA Newswire/ Gaye Gerard

Why this top fund manager is backing gold

Collins St Asset Management says a valuation gap with gold miners is set to close rapidly, potentially within months. Also today: EY prepares to announce layoffs. RBNZ holds rates. Dubber sacks CEO.

David Rogers, Valerina Changarathil and Megan Neil

ManufacturingProperty

Prime Minister Scott Morrison visit to CSL serum lab to inspect COVID-19 Immunoglobulin being produced in Parkville Melbourne. The PM inspects freshly produced vaccine vials. Picture: David Caird POOL IMAGES

International group scoops historic manufacturing site

Animal health company Zoetis has secured a historic manufacturing site in Melbourne’s most prominent biomedical research precinct from the Victorian government.

Trading DayTrading Day

SYDNEY, AUSTRALIA : Newswire Photos AUGUST 30 2023: A general view of the digital boards at the ASX in Sydney. Picture: NCA Newswire/ Gaye Gerard

ASX 200 ends at record high

ASX 200 sets all-time high at close. Life360 soars 38 per cent on earnings beat. ASIC wants crime-linked Prospero wound up. China manufacturing activity better than expected but still weak.

David Rogers, Valerina Changarathil and Megan Neil

EditorialEditorials

Equal pay should lift productivity

Equal pay should lift productivity

It is in companies’ interests to pay staff fairly, regardless of gender.

Editorial

HealthCompanies

hand of scientist holding flask with lab glassware in chemical laboratory background, science laboratory research and development concept istock image

CSL posts ‘strong’ result as plasma division delivers

An ‘exceptional’ performance from its plasma division has underpinned an uplift in first half profit with CSL reaffirming its full year growth outlook.

Cameron England

Trading DayTrading Day

SYDNEY, AUSTRALIA: NewsWire Photos: JANUARY 22 2024: A general view of the digital boards at the ASX in Sydney. Picture: NCA NewsWire / Gaye Gerard

AGL’s Loy Yang hit by outage; ASX closes weaker

ASX 200 closes down 0.2pc at 7603.6points. Loy Yang A station offline. Callide C station failure report out. Macquarie hit by profit warning, star exit. Challenger lifts. Seek, Lew-backed Breville, Seven West and James Hardie fall.

David Rogers, Valerina Changarathil and Megan Neil

MarketsNewsWire

SYDNEY, AUSTRALIA: NewsWire Photos: JANUARY 31 2024: A view of the digital boards at the Australian Stock Exchange in the CBD in sydney. Picture: NCA NewsWire / Gaye Gerard

ASX down as major drug trial scrapped

The Australian sharemarket fell on Monday after biotech giant CSL dropped its plans to continue with a major drug trial.

Aisling Brennan

StockheadStockhead

Not much joy around for CSL at the moment. Picture: Getty Images

Heartbreak as CSL trial disappoints

The news was all bad for CSL when top-line results lobbed from its Phase 3 trial of a treatment to reduce the consequences of heart attacks.

Eddy Sunarto

CommentaryCompanies

Flask in scientist hand and test tubes in rack

CSL will still bet on blockbuster drugs

There were high hopes for a wonder drug being developed by CSL which failed. The pharma giant is still taking the win from the loss.

HealthcareCompanies

HEALTH: Young woman working with liquids in glassware. Biotechnology research laboratory generic

‘Herculean’ CSL drug trial falls flat

The biggest drug trial in CSL’s history, which sought to find a treatment for recurrent cardiac events, has failed to deliver the desired result.

Cameron England

Trading DayTrading Day

SYDNEY, AUSTRALIA: NewsWire Photos: JANUARY 22 2024: A general view of the digital boards at the ASX in Sydney. Picture: NCA NewsWire / Gaye Gerard

CSL drags ASX lower; JB Hi-Fi gains

CSL weighs down market after disappointing cardiac drug trial. Fletcher halts for earnings guidance, CEO future update. Synlait sinks on earnings warning. Retailer JB Hi-Fi up as profit beats estimates.

David Rogers, Valerina Changarathil and Megan Neil

CommentaryBusiness

Operations Supervisor Andrew Leat working on the frozen pipes that contain the -20 degrees CO2 with the well head in the background, at the CO2CRC Otway Project CO2 Storage Research Facility near Peterborough on the West Coast of Victoria.

Carbon capture needs to be more than just aspiration

To combat climate change we must use technology available to us now, such as removing CO2 from processing or industrial facilities, and burying it underground.

Matthias Raab

EXCLUSIVENation

Paul McKenzie, Chief Executive Officer and Managing Director of the biotech company CSL arrives for a State Dinner in honor of Australia's Prime Minister Anthony Albanese and Jodie Haydon, at the Booksellers Room of the White House in Washington, DC on October 25, 2023. (Photo by SAMUEL CORUM / AFP)

Quit RBA board, CSL directors told

Unions want CSL directors Carolyn Hewson and Alison Watkins to quit the RBA board due to CSL’s ‘corporate bastardry’.

EditorialEditorials

Funds must put members first

Funds must put members first

Two powerful trade unions urging eight superannuation funds to review investment in Australia’s third-largest company, CSL, should stick to their day jobs.

Editorial

EXCLUSIVENation

Paul McKenzie, Chief Executive Officer and Managing Director of the biotech company CSL arrives for a State Dinner in honor of Australia's Prime Minister Anthony Albanese and Jodie Haydon, at the Booksellers Room of the White House in Washington, DC on October 25, 2023. (Photo by SAMUEL CORUM / AFP)

Dump CSL, super funds told

Unions declare workers’ funds should not be used to finance CSL’s corporate bastardry.

EXCLUSIVENation

Paul McKenzie, Chief Executive Officer and Managing Director of the biotech company CSL arrives for a State Dinner in honor of Australia's Prime Minister Anthony Albanese and Jodie Haydon, at the Booksellers Room of the White House in Washington, DC on October 25, 2023. (Photo by SAMUEL CORUM / AFP)

Union plan to put boss in dock

CSL chief executive Paul McKenzie faces legal action after exposure of the company’s plan to cut workers’ pay.

Trading DayTrading Day

SYDNEY, AUSTRALIA: Newswire Photos- NOVEMBER 07 2023: A general view of the digital boards at the ASX in Sydney as the Reserve Bank meets today to discuss another rate rise. Photo by: NCA Newswire /Gaye Gerard

ASX gains but post-CPI rally fades

RBA tipped to hold rates next week after inflation cools more than expected. Strong Harvey Norman protest vote as sales slow. Fisher & Paykel, CSL, Temple & Webster among gainers.

Valerina Changarathil, Joseph Carbone and Megan Neil

EXCLUSIVENation

Paul McKenzie, Chief Executive Officer and Managing Director of the biotech company CSL arrives for a State Dinner in honor of Australia's Prime Minister Anthony Albanese and Jodie Haydon, at the Booksellers Room of the White House in Washington, DC on October 25, 2023. (Photo by SAMUEL CORUM / AFP)

Revealed: CSL’s secret plan to cut pay, sack workers

Australia’s third biggest company devised a plan to shift workers on to lower pay and conditions and make them redundant if they refused to relocate.

Money Puzzle podcastWealth

(FILES) This photograph taken on February 23, 2023, in Paris, shows the anti-diabetic medication

The Ozempic effect

The weight loss drug is causing market value losses at healthcare leaders such as CSL and ResMed – but when will the market pay attention to the limits of what Ozempic may offer?

Trading DayTrading Day

SYDNEY, AUSTRALIA : Newswire Photos AUGUST 30 2023: A general view of the digital boards at the ASX in Sydney. Picture: NCA Newswire/ Gaye Gerard

ASX 200 down; Treasury Wine gets first strike

Protest vote lodged against winemaker’s remuneration. Qantas down as oil prices jump, loyalty boss quits. Fletcher plunges on Iplex claims. Liontown hit with downgrades as Albemarle walks away.

David Rogers, Valerina Changarathil and Megan Neil

COMMENTARYBusiness

Sturt Krygsman illustration of Brian McNamee (CSL Chair) for the business pages on 14/10/2023 Version: Business Cartoon (1280x720 - Aspect ratio preserved, Canvas added) COPYRIGHT: The Australian's artists each have different copyright agreements in place regarding re-use of their work in other publications. Please seek advice from the artists themselves or the Managing Editor of The Australian regarding re-use.

CSL to feel the Bunsen burner over its Vifor acquisition

CSL’s falling share price on the back of the success of competitor Novo’s wonder-drug Ozempic is raising uncomfortable questions over its $18.2bn purchase of Vifor.

Trading DayTrading Day

SYDNEY, AUSTRALIA - NewsWire Photos - APRIL 18 2023 - A general view of people walking past the ASX in Central Sydney. Picture NCA NewsWire / Gaye Gerard

ASX ends down; CSL rebounds

Court finds ANZ failed to inform market over 2015 placement. China’s flat inflation signals need for stimulus. Fletcher Building dismisses BGC’s plumbing claims. Perpetual lifts. Pact rejects billionaire investor’s bid.

David Rogers, Valerina Changarathil and Megan Neil

Trading DayTrading Day

SYDNEY, AUSTRALIA - Newswire Photos - JULY 25 2023:A view of the Digital boards at the Sydney ASX. Picture: NCA Newswire / Gaye Gerard

ASX ends flat; CSL tumbles to four-year low

CSL sinks past Covid lows. PwC former boss Luke Sayers tells Senate inquiry he feels terrible, but there were a ‘number of bad actor tax partners’. Tabcorp tanks. CBA tips ‘live’ RBA meeting. Redbubble soars.

David Rogers, Valerina Changarathil and Megan Neil

Biotech giantCompanies

CSL chief executive Paul McKenzie with chairman Brian McNamee.Picture: Supplied

‘We’re listening’: CSL avoids strike as investors vent

The third-largest company on the ASX narrowly avoided a first strike as investors took the biotechnology player to task on plans to award performance rights to the CEO.

Trading DayTrading Day

SYDNEY, AUSTRALIA - Newswire Photos AUGUST 07 2023: A general view of the digital boards at the ASX in Sydney as interest rates continue to rise. Picture NCA Newswire/ Gaye Gerard

ASX up; Rinehart ups Liontown stake

Gina Rinehart’s Hancock Prospecting has 19.9 per cent of Liontown. CSL avoids first strike. Profit fall, outlook weighs on BoQ. Qantas gains on chair exit.

David Rogers, Valerina Changarathil and Megan Neil

StockheadStockhead

'Hey, it might be worth taking a plunge on these stocks.' Picture: Getty Images

Brokers splash upgrades on pool of stocks

Amid what seems like share market doom and gloom, brokers have a bright outlook on stocks across various sectors, including one with a 33 per cent upside.

Nadine McGrath

Trading DayTrading Day

SYDNEY, AUSTRALIA - NewsWire photos AUGUST 29, 2023: ASX in Sydney. Picture: NCA NewsWire / Dylan Coker

ASX 200 rises despite energy falls

Low oil price hits Woodside, Santos. Lithium miners fall on JP Morgan downgrade. Union bid to expand IR laws. Trade surplus up more than expected. AUD gains.

David Rogers, Valerina Changarathil and Megan Neil

Trading DayTrading Day

SYDNEY, AUSTRALIA - NCA NewsWire Photos - Monday, 25 SEPTEMBER, 2023: EMPLOYMENT ECONOMICS ASX stock images Picture: NCA NewsWire / Monique Harmer

ASX ends down; RBA keeps rates on hold

RBA holds rates at 4.1pc for fourth month. Inflation still too high: Bullock. US sale lifts Computershare. Avita tanks on new FDA hurdle. US, Aus bond yields hit new highs. Endeavour allows Wavish vote.

David Rogers, Valerina Changarathil and Megan Neil

BiotechMedical

28 year-old Tara Seaton, an Australia Post employee, looks away as Luiza Duszynski, a nursing supervisor at the Royal Adelaide Hospital, injects her with CSL Ltd.'s H1N1 vaccine in Adelaide, Australia, on Wednesday, July 22, 2009. The first human trials of a swine-flu vaccine began today in Australia as deaths and infections from the H1N1 virus mount worldwide, intensifying demand for a protective shot. Photographer: Carla Gottgens/Bloomberg

CSL’s ‘super flu jab’ gets a shot in the arm

Australia’s biggest health company has revealed its flu shot is 15pc more effective than conventional ones. But don’t expect the government to pay for it.

Pandemic preparednessCompanies

28 year-old Tara Seaton, an Australia Post employee, looks away as Luiza Duszynski, a nursing supervisor at the Royal Adelaide Hospital, injects her with CSL Ltd.'s H1N1 vaccine in Adelaide, Australia, on Wednesday, July 22, 2009. The first human trials of a swine-flu vaccine began today in Australia as deaths and infections from the H1N1 virus mount worldwide, intensifying demand for a protective shot. Photographer: Carla Gottgens/Bloomberg

CSL inks deal with UK govt for 100m flu shots

Most people would groan at the thought of a future pandemic, but governments are determined not be caught out again, with the UK striking a new deal with CSL.

1
2
3
4
5
…
12

Original URL: https://www.theaustralian.com.au/topics/csl/page/3